Differentiating Fat Necrosis from Malignancy in fat grafted breasts. A new Study.

Posted on October 29, 2012

Journal time.  October 2012 issue of Plastic and Reconstructive Surgery Journal was full of interesting studies as always.  This one really drew my attention.  “Differentiating Fat Necrosis from Recurrent Malignancy in Fat Grafted Breasts: An Imaging Classification system to Guide Management.

English translation:

When you transfer fat to a breast, the newly transferred fat can die.  When fat dies it can form a calcification.  This tends to be a microcalcification- you can’t feel it, but you see it on mammogram.  A big issue with fat transfer in patients with a strong family history of breast cancer, a personal history of breast cancer, or issues with breast imaging, is if you do fat transfer and get calcifications or palpable masses, how can you tell what calcifications are from the fat transfer and which ones could mean breast cancer?

Big issue.  This is why fat transfer to the breast had not been done for so long.  So this study is looking at the films

 Is there a way to create a standard for mammograms to distinguish

which lesions are benign (not cancer) from malignant (cancer) after fat grafting?

Study:

Findings?

So, they conclude ultrasound analysis and a standardized classification system is reliable at telling the difference between benign fat necrosis and a malignant breast cancer after patients have had breast reconstruction using fat transfer. 

This study was done on palpable masses. 

The authors suggest if doing fat transfer in someone who has a history of breast cancer, follow up should be done at regular intervals, with ultrasound analysis and an objective classification of the palpable lesion, and integrated care by a team of the patient, an experienced radiologist, a breast surgeon, and the plastic surgeon.

I applaud this study and those like it.  We need to keep demonstrating patient safety is not compromised for improved aesthetic results.  Fat transfer, to be widely accepted as a breast cancer reconstructive technique, needs to continue to alleviate concerns of risk.  This study shows a simple classification framework can help distinguish benign masses from recurrent cancer.